MarketResearchReports.Biz announces addition of new report “Competitor Analysis ErbB / Her Receptor Antagonists” to its database
Albany, NY -- (SBWIRE) -- 08/06/2013 -- The present Competitive Intelligence Report about antagonists of the ErbB/Her receptor pathway provides a competitor evaluation in the field of ErbB1 (EGF-R), ErbB2 (Her), ErbB3 (Her) and ErbB4 (Her4) receptor targeting molecules for treatment of cancer as of July 2013. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
To Read The Complete Report with TOC : http://www.marketresearchreports.biz/analysis-details/competitor-analysis-erbb--her-receptor-antagonists
Targeted treatment of EGF-R and Her2-positive cancers with target specific antibodies has become an example of successful personalized medicine. The commercial success of small molecule ErbB/Her receptor tyrosine kinase inhibitors and EGF-R and Her2 targeted antibody therapy has spurred the discovery and development of efficacy enhanced versions as well as of ErbB dual or multi-target therapies.
To Buy A Copy Of This Report Visit : http://www.marketresearchreports.biz/analysis/171550
The report includes a compilation of current active projects in research and development of molecules targeting the receptors of the ErbB/Her family. In addition the report lists company-specific R&D pipelines of ErbB/Her receptor targeting molecular entities.
90 Sate Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-997-4948